BVS vs LYFT
BVS: Bioventus is an orthopedic medical technology company focused on pain relief and musculoskeletal treatment through hyaluronic acid viscosupplements, bone growth stimulators, and emerging surgical and regenerative medicine platforms. LYFT: A global ridesharing and multimodal mobility platform connecting millions of riders and drivers across thousands of cities, recently expanded through acquisitions of European taxi and luxury chauffeur services.
Side-by-side fundamentals
| Metric | BVS | LYFT | Edge |
|---|---|---|---|
| Price as of 2026-08-11 close | $13.85 | $17.54 | |
| Market cap as of 2026-08-12 | $1.2B | $6.6B | |
| P/E as of 2026-08-12 | 41.22 | 2.30 | LYFT lower |
| PEG as of 2026-08-12 | 3.20 | -0.06 | LYFT lower |
| Net margin as of 2026-08-12 | +4.9% | +42.3% | LYFT higher |
| Gross margin as of 2026-08-12 | +68.7% | +38.0% | BVS higher |
| Operating margin as of 2026-08-12 | +9.9% | -1.8% | BVS higher |
| ROE as of 2026-08-12 | +16.3% | +115.8% | LYFT higher |
| ROA as of 2026-08-12 | +4.2% | +34.8% | LYFT higher |
| Debt / equity as of 2026-08-12 | 1.49 | 0.37 | LYFT lower |
| Revenue growth (YoY) as of 2026-08-12 | +1.5% | +10.8% | LYFT higher |
| Revenue CAGR (3y) SEC XBRL | +3.5% | +15.6% | LYFT higher |
| Beta as of 2026-08-12 | 0.68 | 1.96 | |
| 1-year return as of 2026-08-11 close | +99.9% | +30.3% | BVS higher |
Fundamentals: market data, as of 2026-08-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-11.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.